Single Nucleotide Polymorphisms and Long-Term Clinical Outcome in Renal Transplant Patients: A Validation Study

Area of Science:

• Genetics
• Transplantation Immunology
• Clinical Outcomes Research

Background:

• Genome-wide association studies (GWAS) identify genetic variants associated with clinical phenotypes.
• A prior GWAS suggested two single nucleotide polymorphisms (SNPs), rs3811321 and rs6565887, were linked to serum creatinine and outcomes in renal transplant recipients.

Purpose of the Study:

• To validate the association of rs3811321 and rs6565887 with clinical outcomes in a larger cohort of renal transplant recipients.
• To assess the impact of these SNPs on death-censored graft loss and all-cause mortality.

Main Methods:

• Genotyping of rs3811321 and rs6565887 was performed using Taqman assays in 1638 Caucasian participants of the Assessment of LEscol in Renal Transplant (ALERT) study.
• Cox regression analysis was employed to evaluate the association with primary (death-censored graft loss) and secondary (all-cause mortality) endpoints.

Main Results:

• No significant association was found between rs3811321 (HR 0.87, p=0.50) or rs6565887 (HR 0.88, p=0.48) and death-censored graft loss.
• Multivariable adjustments and analysis of combined risk alleles did not alter these findings.
• No association with all-cause mortality was detected for either SNP.

Conclusions:

• The identified SNPs (rs3811321 and rs6565887) on chromosomes 14 and 18 were not confirmed to influence death-censored graft survival or all-cause mortality in this cohort.
• These results underscore the critical importance of validating genetic findings from high-throughput studies.
• The study calls for large-scale collaborative research to advance understanding of transplantation outcomes.